135 related articles for article (PubMed ID: 31870839)
1. Effects of inflammation on irinotecan pharmacokinetics and development of a best-fit PK model.
Chityala PK; Wu L; Chow DS; Ghose R
Chem Biol Interact; 2020 Jan; 316():108933. PubMed ID: 31870839
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
4. Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.
Guan HY; Li PF; Wang XM; Yue JJ; He Y; Luo XM; Su MF; Liao SG; Shi Y
Front Pharmacol; 2017; 8():769. PubMed ID: 29163158
[TBL] [Abstract][Full Text] [Related]
5. A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection.
Zhuang Q; Liu X; Sun Z; Wang H; Jiang J
J Pharm Biomed Anal; 2019 Jun; 170():112-123. PubMed ID: 30921645
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
Eur J Clin Pharmacol; 2019 Apr; 75(4):529-542. PubMed ID: 30610273
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
10. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Mallick P; Shah P; Gandhi A; Ghose R
Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
[TBL] [Abstract][Full Text] [Related]
11. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Mick R; Gupta E; Vokes EE; Ratain MJ
J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
[TBL] [Abstract][Full Text] [Related]
13. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt.
Sun R; Zhu L; Li L; Song W; Gong X; Qi X; Wang Y; Ghose R; Gao S; Hu M; Liu Z
Toxicol Appl Pharmacol; 2020 Jul; 398():115032. PubMed ID: 32387182
[TBL] [Abstract][Full Text] [Related]
15. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Tsuboya A; Kubota Y; Ishida H; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Sasaki Y; Matsumoto N; Kondo Y; Tomoda Y; Kusuhara H; Fujita KI
Cancer Chemother Pharmacol; 2021 Sep; 88(3):543-553. PubMed ID: 34117512
[TBL] [Abstract][Full Text] [Related]
16. Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.
Karas S; Etheridge AS; Tsakalozou E; Ramírez J; Cecchin E; van Schaik RHN; Toffoli G; Ratain MJ; Mathijssen RHJ; Forrest A; Bies RR; Innocenti F
AAPS J; 2020 Mar; 22(3):59. PubMed ID: 32185579
[TBL] [Abstract][Full Text] [Related]
17. Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea.
Sun R; Basu S; Zeng M; Sunsong R; Li L; Ghose R; Wang W; Liu Z; Hu M; Gao S
Curr Cancer Drug Targets; 2019; 19(7):551-560. PubMed ID: 31509102
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study.
Marangon E; Posocco B; Mazzega E; Toffoli G
PLoS One; 2015; 10(2):e0118194. PubMed ID: 25689738
[TBL] [Abstract][Full Text] [Related]
19. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Horita Y; Yamada Y; Hirashima Y; Kato K; Nakajima T; Hamaguchi T; Shimada Y
Cancer Chemother Pharmacol; 2010 Feb; 65(3):467-71. PubMed ID: 19554330
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
